IQVIA Hldgs Analyst Ratings
Evercore ISI Group Maintains Outperform on IQVIA Hldgs, Lowers Price Target to $230
Goldman Sachs Maintains Neutral on Mettler-Toledo Intl, Raises Price Target to $1300
Mettler-Toledo Intl Analyst Ratings
RBC Raises Price Target on Vertex Pharmaceuticals to $431 From $421, Keeps Sector Perform Rating
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating
RBC Cuts Price Target on Biogen to $303 From $317, Keeps Outperform Rating
Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating
UBS Keeps Their Hold Rating on Argenx Se (ARGX)
Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $357
Goldman Sachs Adjusts Price Target on Mettler-Toledo International to $1,300 From $1,150, Maintains Neutral Rating
Gilead Sciences Analyst Ratings
Raymond James Upgrades Gilead Sciences to Outperform, Announces $93 Price Target
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Alnylam Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160
Mettler-Toledo Intl Analyst Ratings
Evercore ISI Adjusts Price Target on Mettler-Toledo International to $1,390 From $1,375, Maintains In-line Rating